| Followers | 35 |
| Posts | 2237 |
| Boards Moderated | 0 |
| Alias Born | 10/18/2019 |
Saturday, May 25, 2024 11:43:16 AM
Manibiotec, yes I agree, l looked at 1 Mont, 3 month, ytd, 6 month, one year, and 3 year chart and yesterday posted that all are down. The 4 and 5 year charts show gains but in this stock I go back to 2015 and is not a nice chart. It was my decision but many years back I sold another stock to purchase more nwbo and that other stock went well over $100 a share and nwbo (at least to now) is a very far cry from 100+ a share. I have talked utmost respect for the researchers but took me a long time to take what I hear from nwbo with a grain of salt. I used to speak with Les Goldman at least every month and I do like the guy but imo they lack the experience to move forward in a timely manner. I have often thought they should add a person with such experience to the management team. They have a good product (imo) but certainly has been a struggle to get it to market. Dilution in such companies is expected but when I started the outstanding shares were less than 100 million and now a bit higher than that - like 10 to 15 times. Imo the statement from LP that all big pjarma brings is a checkbook, well they needed that checkbook. I still think they should get approval in UK but the real potential revenue comes with fda approval and as the vaccine is at least as good as temozolomide (part of soc) imo should also be able to get US approval. Both temozolomide and dcvax add at median about 3 months to os and dcvax has the long tail survivors. Partner up and get this thing out there
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
